Advertisement

Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study

Published:November 05, 2022DOI:https://doi.org/10.1016/j.jiac.2022.10.019

      Abstract

      Introduction

      Pneumocystis pneumonia (PCP) is an opportunistic lung infection and has been reported among patients with rheumatoid arthritis (RA). An animal study revealed that sulfasalazine enhances Pneumocystis clearance from the lung by accelerating macrophage activity.

      Methods

      The self-controlled case series (SCCS) method was used to investigate the association between sulfasalazine use and PCP development in patients with RA without the effect of time-invariant, interpatient confounders. PCP episodes which developed in patients with RA at five hospitals between 2003 and 2019 were identified. PCP was defined by the following criteria: 1) detection of Pneumocystis jirovecii in respiratory specimens by polymerase chain reaction; 2) clinical symptoms (pyrexia, dry cough, dyspnea or hypoxia); 3) diffuse interstitial infiltrate on chest imaging; and 4) absence of PCP prophylaxis. The PCP incidence rate ratio (IRR) was compared between periods with and without sulfasalazine use by conditional Poisson regression.

      Results

      Fifty episodes of PCP were identified in 49 patients. Thirty patients received sulfasalazine at some point during their observation. While 49 episodes of PCP developed in 170.3 person-years without sulfasalazine use, only one episode of PCP developed in 103.7 person-years with sulfasalazine use. Sulfasalazine use was associated with a decreased PCP risk (adjusted IRR <0.01; 95% confidence interval <0.01–0.03) after adjusting for age and glucocorticoid, methotrexate, and tumor necrosis factor inhibitor administration.

      Conclusion

      Our study demonstrated a preventive effect of sulfasalazine against PCP in patients with RA.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ward M.M.
        • Donald F.
        Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.
        Arthritis Rheum. 1999; 42: 780-789https://doi.org/10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M
        • Hsu H.C.
        • Chang Y.S.
        • Hou T.Y.
        • et al.
        Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.
        Clin Rheumatol. 2021; 40: 3755-3763https://doi.org/10.1007/s10067-021-05660-4
        • Sato T.
        • Inokuma S.
        • Maezawa R.
        • et al.
        Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases.
        Mod Rheumatol. 2005; 15: 191-197https://doi.org/10.1007/s10165-005-0395-9
        • Teichtahl A.J.
        • Morrisroe K.
        • Ciciriello S.
        • et al.
        Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients.
        Semin Arthritis Rheum. 2015; 45: 86-90https://doi.org/10.1016/j.semarthrit.2015.01.007
        • LeMense G.P.
        • Sahn S.A.
        Opportunistic infection during treatment with low dose methotrexate.
        Am J Respir Crit Care Med. 1994; 150: 258-260https://doi.org/10.1164/ajrccm.150.1.8025760
        • Stenger A.A.
        • Houtman P.M.
        • Bruyn G.A.
        • et al.
        Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis.
        Scand J Rheumatol. 1994; 23: 51-53https://doi.org/10.3109/03009749409102137
        • Kaur N.
        • Mahl T.C.
        Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
        Dig Dis Sci. 2007; 52: 1481-1484https://doi.org/10.1007/s10620-006-9250-x
        • Koike T.
        • Harigai M.
        • Inokuma S.
        • et al.
        Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.
        Ann Rheum Dis. 2011; 70: 2148-2151https://doi.org/10.1136/ard.2011.151092
        • Koike T.
        • Harigai M.
        • Inokuma S.
        • et al.
        Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis.
        Mod Rheumatol. 2011; 21: 343-351https://doi.org/10.3109/s10165-010-0406-3
        • Koike T.
        • Harigai M.
        • Ishiguro N.
        • et al.
        Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
        Mod Rheumatol. 2012; 22: 498-508https://doi.org/10.3109/14397595.2013.843760
        • Takeuchi T.
        • Tatsuki Y.
        • Nogami Y.
        • et al.
        Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
        Ann Rheum Dis. 2008; 67: 189-194https://doi.org/10.1136/ard.2007.072967
        • Mori S.
        • Sugimoto M.
        Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis.
        Rheumatology. 2012; 51: 2120-2130https://doi.org/10.1093/rheumatology/kes244
        • Lesch J.E.
        The discovery of M & B 693 (sulfapyridine). vol. 16. Publ Am Inst Hist Pharm, 1997: 101-119
        • Wang J.
        • Gigliotti F.
        • Bhagwat S.P.
        • et al.
        Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage- mediated fungal clearance during Pneumocystis pneumonia.
        PLoS Pathog. 2010; 6: 59-60https://doi.org/10.1371/journal.ppat.1001058
        • Nunokawa T.
        • Yokogawa N.
        • Shimada K.
        • et al.
        Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: a nested case-control study.
        Semin Arthritis Rheum. 2019; 48: 573-578https://doi.org/10.1016/j.semarthrit.2018.05.013
        • Nunokawa T.
        • Yokogawa N.
        • Shimada K.
        • et al.
        Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: a test-negative design case-control study with PCR tests.
        Mod Rheumatol. 2019; 29: 436-440https://doi.org/10.1080/14397595.2018.1465647
        • Didiodato G.
        • Fruchter L.
        Antibiotic exposure and risk of community-associated Clostridium difficile infection: a self-controlled case series analysis.
        Am J Infect Control. 2019; 47: 9-12https://doi.org/10.1093/ofid/ofx163.996
        • Petersen I.
        • Douglas I.
        • Whitaker H.
        Self controlled case series methods: an alternative to standard epidemiological study designs.
        BMJ. 2016; 354: i4515https://doi.org/10.1136/bmj.i4515
        • Whitaker H.J.
        • Farrington C.P.
        • Spiessens B.
        • et al.
        Tutorial in biostatistics: the self-controlled case series method.
        Stat Med. 2006; 25: 1768-1797https://doi.org/10.1002/sim.2302
        • Komano Y.
        • Harigai M.
        • Koike R.
        • et al.
        Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.
        Arthritis Rheum. 2009; 61: 305-312https://doi.org/10.1002/art.24283
        • Tokuda H.
        • Sakai F.
        • Yamada H.
        • et al.
        Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study.
        Inter Med. 2008; 47: 915-923https://doi.org/10.2169/internalmedicine.47.0702
        • Yukawa K.
        • Nagamoto Y.
        • Watanabe H.
        • et al.
        Risk factors for pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim/sulfamethoxazole.
        J Clin Rheumatol. 2018; 24: 355-360https://doi.org/10.1097/RHU.0000000000000731
        • Farrington P.
        • Whitaker H.
        • Ghebremichael Weldeselassie Y.
        The standard SCCS model.
        in: Chow S.C. Jones B. Liu J.P. Peace K.E. Turnbull B.W. Self-controlled case series studies. Chapman and Hall/CRC, New York2018: 47-101
        • Cooley L.
        • Dendle C.
        • Wolf J.
        • et al.
        Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies.
        Intern Med J. 2014; 44 (2014): 1350-1363https://doi.org/10.1111/imj.12599
        • Ioannidis J.P.
        • Cappelleri J.C.
        • Skolnik P.R.
        • et al.
        A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
        Arch Intern Med. 1996; 156: 177-188https://doi.org/10.1001/archinte.1996.00440020081010
        • Park J.W.
        • Curtis J.R.
        • Moon J.
        • et al.
        Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
        Ann Rheum Dis. 2018; 77: 644-649https://doi.org/10.1136/annrheumdis-2017-211796
        • Park J.W.
        • Curtis J.R.
        • Kim M.J.
        • et al.
        Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
        Arthritis Res Ther. 2019; 21: 1-10https://doi.org/10.1186/s13075-019-1996-6
        • Mecoli C.A.
        • Saylor D.
        • Gelber A.C.
        • et al.
        Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
        Clin Exp Rheumatol. 2017; 35: 671-673
        • Ghembaza A.
        • Vautier M.
        • Cacoub P.
        • et al.
        Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases.
        Chest. 2020; 158: 2323-2332https://doi.org/10.1016/j.chest.2020.05.558
        • Stern A.
        • Green H.
        • Paul M.
        • et al.
        Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
        Cochrane Database Syst Rev. 2014; : CD005590https://doi.org/10.1002/14651858.CD005590.pub3
        • Green H.
        • Paul M.
        • Vidal L.
        • et al.
        Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.
        Mayo Clinic. 2007; 82: 1052-1059https://doi.org/10.4065/82.9.1052
        • Vananuvat P.
        • Suwannalai P.
        • Sungkanuparph S.
        • et al.
        Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
        Semin Arthritis Rheum. 2011; 41: 497-502https://doi.org/10.1016/j.semarthrit.2011.05.004
        • Kameda H.
        • Tokuda H.
        • Sakai F.
        • et al.
        Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study.
        Inter Med. 2011; 50: 305-313https://doi.org/10.2169/internalmedicine.50.4508
        • Limper A.H.
        • Offord K.P.
        • Smith T.F.
        • et al.
        Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS.
        Am Rev Respir Dis. 1989; 140: 1204-1209https://doi.org/10.1164/ajrccm/140.5.1204
        • Katsuyama T.
        • Saito K.
        • Kubo S.
        • et al.
        The prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.
        Arthritis Res Ther. 2014; 16: R43https://doi.org/10.1186/ar4472
        • Theel E.S.
        • Jespersen D.J.
        • Iqbal S.
        • et al.
        Detection of (1, 3)-β-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts.
        Mycopathologia. 2013; 175: 33-41https://doi.org/10.1007/s11046-012-9579-y
        • Del Corpo O.
        • Butler-Laporte G.
        • Sheppard D.C.
        • et al.
        Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis.
        Clin Microbiol Infect. 2020; 26: 1137-1143https://doi.org/10.1016/j.cmi.2020.05.024
        • Louie G.H.
        • Wang Z.
        • Ward M.M.
        Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007.
        Arthritis Rheum. 2010; 62: 3826-3827https://doi.org/10.1002/art.27735
        • Bruce E.S.
        • Kearsley-Fleet L.
        • Watson K.D.
        • et al.
        Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
        Rheumatology. 2016; 55: 1336-1337https://doi.org/10.1093/rheumatology/kew200